CoChat
Sign Up
Cited by 11Blood Pressure and Hypertension StudiesHormonal Regulation and HypertensionCardiovascular Health and Disease Prevention

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Long-acting nifedipine in the management of essential hypertension: a review for cardiologists

Open access
Hazra, Prakash Kumar·2024·American Journal of Cardiovascular Disease
DOI 10.62347/rpmz6407PMC PMC11744219
Open this paper in CoChat — free account

Abstract

Calcium channel antagonists, specifically long-acting nifedipine formulations, play a crucial role in treating hypertension and angina. Originally used for angina, nifedipine has been widely employed as an antihypertensive medication for over 40 years. It offers rapid action and oral bioavailability with minimal maternal or fetal side effects, making it suitable for treating hypertensive crises during pregnancy. However, it can cause a sudden drop in blood pressure and tachycardia. Long-acting formulations, such as gastrointestinal therapeutic systems, gradually release nifedipine over 24 hours, mitigating these issues. This review aims to assess the clinical efficacy and safety of long-acting nifedipine formulations in managing essential hypertension, with a focus on improving blood pressure control and addressing challenges in uncontrolled and resistant hypertension. Furthermore, long-acting nifedipine provides therapeutic advantages beyond hypertension management, showing efficacy in treating comorbid conditions such as chronic kidney disease and diabetes. Global studies support its efficacy, suggesting that a shift toward the use of long-acting nifedipine can help address the global hypertension problem and enhance the quality of life for hypertensive patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.62347/rpmz6407

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 90

  1. Messerli FH, Williams B and Ritz E. Essential hypertension. Lancet 2007; 370: 591-603. · DOI
  2. Fatima S and Mahmood S. Combatting a silent killer - the importance of self-screening of blood pressure from an early age. EXCLI J 2021; 20: 1326-1327.
  3. Nguyen TN and Chow CK. Global and national high blood pressure burden and control. Lancet 2021; 398: 932-933. · DOI
  4. Prenissl J, Manne-Goehler J, Jaacks LM, Prabhakaran D, Awasthi A, Bischops AC, Atun R, Bärnighausen T, Davies JI, Vollmer S and Geldsetzer P. Hypertension screening, awareness, treatment, and control in India: a nationally representative cross-sectional study among individuals aged 15 to 49 years. PLoS Med 2019; 16: e1002801. · DOI
  5. Ramakrishnan S, Zachariah G, Gupta K, Shivkumar Rao J, Mohanan PP, Venugopal K, Sateesh S, Sethi R, Jain D, Bardolei N, Mani K, Kakar TS, Kidambi B, Bhushan S, Verma SK, Bhargava B, Roy A, Kothari SS, Gupta R, Bansal S, Sood S, Nath RK, Tyagi S, Gupta MD, Girish MP, Kalra IPS, Wander GS, Gupta S, Mandal S, Senguttuvan NB, Subramanyam G, Roy D, Datta S, Ganguly K, Routray SN, Mishra SS, Singh BP, Bharti BB, Das MK, Kumar S, Goswami KC, Bahl VK, Chandra S, Banerjee A, Guha S, Deb PK, Chopra HK, Deedwania P and Seth A; CSI-Great India BP Campaign Investigators. Prevalence of hypertension among Indian adults: results from the great India blood pressure survey. Indian Heart J 2019; 71: 309-313. · DOI
  6. Shah SN, Munjal YP, Kamath SA, Wander GS, Mehta N, Mukherjee S, Kirpalani A, Gupta P, Shah H, Rohatgi R, Billimoria AR, Maiya M, Das MK, Goswami KC, Sharma R, Rajapurkar MM, Chawla R, Saboo B and Jha V. Indian guidelines on hypertension-IV (2019). J Hum Hypertens 2020; 34: 745-758. · DOI
  7. Snider ME, Nuzum DS and Veverka A. Long-acting nifedipine in the management of the hypertensive patient. Vasc Health Risk Manag 2008; 4: 1249-1257. · DOI
  8. Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, Daly C, De Backer G, Hjemdahl P, Lopez-Sendon J, Marco J, Morais J, Pepper J, Sechtem U, Simoons M, Thygesen K, Priori SG, Blanc JJ, Budaj A, Camm J, Dean V, Deckers J, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo J, Zamorano JL, Andreotti F, Becher H, Dietz R, Fraser A, Gray H, Antolin RAH, Huber K, Kremastinos DT, Maseri A, Nesser HJ, Pasierski T, Sigwart U, Tubaro M and Weis M. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the management of stable angina pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341-1381. · DOI
  9. Evbayekha EO, Okobi OE, Okobi T, Ibeson EC, Nwafor JN, Ozobokeme OE, Olawoye A, Ngoladi IA, Boms MG, Habib FA, Oyelade BO, Okoroafor CC, Chukwuma VN, Alex KB and Ohikhuai EE. The evolution of hypertension guidelines over the last 20+ years: a comprehensive review. Cureus 2022; 14: e31437. · DOI
  10. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD and Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Hypertension 2018; 71: e13-e115. · DOI · Paper page
  11. Brettler J. BMJ Best Practice Essential hypertension. https://bestpractice.bmj.com/topics/en-gb/26.
  12. Kumar V, Agarwal S, Saboo B and Makkar B. RSSDI Guidelines for the management of hypertension in patients with diabetes mellitus. Int J Diabetes Dev Ctries 2022; 42: 576-605. · DOI
  13. Sarafidis PA and Bakris GL. Resistant hypertension: an overview of evaluation and treatment. J Am Coll Cardiol 2008; 52: 1749-1757. · DOI
  14. Tobe SW and Lewanczuk R. Resistant hypertension. Can J Cardiol 2009; 25: 315-317. · DOI
  15. Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty SL, Dennison-Himmelfarb CR, Egan BM, Flack JM, Gidding SS, Judd E, Lackland DT, Laffer CL, Newton-Cheh C, Smith SM, Taler SJ, Textor SC, Turan TN and White WB; American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council. Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension 2018; 72: e53-e90. · DOI · Paper page
  16. Acelajado MC, Hughes ZH, Oparil S and Calhoun DA. Treatment of resistant and refractory hypertension. Circ Res 2019; 124: 1061-1070. · DOI
  17. Mavani S, Abraham M, Conjeevaram A, Singh S, Revandkar V and Birla A. Nicardia® XL (nifedipine extended release): technologically advanced GITS formulation ensures robust efficacy and assured safety. Journal of Drug Delivery and Therapeutics 2022; 12: 181-191. · DOI
  18. Reams G, Lau A, Knaus V and Bauer JH. The effect of nifedipine GITS on renal function in hypertensive patients with renal insufficiency. J Clin Pharmacol 1991; 31: 468-472. · DOI
  19. Meredith PA and Elliott HL. A review of the gastrointestinal therapeutic system (GITS) formulation and its effectiveness in the delivery of antihypertensive drug treatment (focus on nifedipine GITS). Integr Blood Press Control 2013; 6: 79-87. · DOI
  20. Cramer MP and Saks SR. Translating safety, efficacy and compliance into economic value for controlled release dosage forms. Pharmacoeconomics 1994; 5: 482-504. · DOI
  21. Vetrovec GW. Once-daily therapy for angina pectoris with nifedipine gastrointestinal therapeutic system. Dosing and clinical efficacy. Am J Med 1989; 86: 28-32. · DOI
  22. Kawano H, Ashizawa N, Toda G, Seto S and Yano K. Administration of nifedipine CR immediately after awakening prevents a morning surge in hypertensive patients. Case report of three cases. Blood Press Suppl 2003; 1: 44-48. · DOI
  23. Granberry MC, Gardner SF, Schneider EF and Carter IR. Comparison of two formulations of nifedipine during 24-hour ambulatory blood pressure monitoring. Pharmacotherapy 1996; 16: 932-936. · DOI
  24. Carr AA, Bottini PB, Feig P, Prisant LM, Mulligan S, Devane JG, Fisher L, Rhoades RB and MacCarthy EP. Effectiveness of once-daily monotherapy with a new nifedipine sustained release calcium antagonist. Am J Cardiol 1992; 69: 28E-32E. · DOI
  25. Toal CB, Mahon WA, Barnes C and Burelle D. Nifedipine gastrointestinal therapeutic system (GITS) for hypertensive patients in a primary care setting: results of the Extended Release Adalat Canadian Trial (EXACT). Clin Ther 1997; 19: 924-935. · DOI
  26. Bittar N, Corder CN, Eich R, McGrew FA 3rd, Paulk EA and Zellner S. Efficacy of nifedipine gastrointestinal therapeutic system in combination with beta blockers in the management of exertional angina. A multicenter study of 54 patients. Am J Med 1987; 83: 30-33. · DOI
  27. Ueng KC, Lin MC, Chan KC and Lin CS. Nifedipine gastrointestinal therapeutic system: an overview of its antiatherosclerotic effects. Expert Opin Drug Metab Toxicol 2007; 3: 769-780. · DOI
  28. Reams GP, Lau A and Bauer JH. Short-term and long-term renal response to nifedipine monotherapy. Am J Hypertens 1989; 2: 188-190. · DOI
  29. Zhang J, Wang Y, Hu H, Yang X, Tian Z, Liu D, Gu G, Zheng H, Xie R and Cui W. Early intervention of long-acting nifedipine GITS reduces brachial-ankle pulse wave velocity and improves arterial stiffness in Chinese patients with mild hypertension: a 24-week, single-arm, open-label, prospective study. Drug Des Devel Ther 2016; 10: 3399-3406. · DOI
  30. ENCORE Investigators. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation 2003; 107: 422-428. · DOI
  31. Devereux RB, Palmieri V, Sharpe N, De Quattro V, Bella JN, de Simone G, Walker JF, Hahn RT and Dahlöf B. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation 2001; 104: 1248-1254. · DOI
  32. Textor SC, Schwartz L, Wilson DJ, Wiesner R, Romero JC, Augustine J, Kos P, Hay E, Gores G and Dickson ER. Systemic and renal effects of nifedipine in cyclosporine-associated hypertension. Hypertension 1994; 23 Suppl: I220-4. · DOI
  33. Kuga K, Xu DZ, Ohtsuka M, Aonuma K, Lau AH, Watanabe Y and Ohtsuka K. Comparison of daily anti-hypertensive effects of amlodipine and nifedipine coat-core using ambulatory blood pressure monitoring - utility of “hypobaric curve” and “hypobaric area”. Clin Exp Hypertens 2011; 33: 231-239. · DOI
  34. Fukuda M, Masuda T, Ogura MN, Moriya T, Tanaka K, Yamamoto K, Ishii A, Yonezawa R, Noda C and Izumi T. Influence of nifedipine coat-core and amlodipine on systemic arterial stiffness modulated by sympathetic and parasympathetic activity in hypertensive patients. Hypertens Res 2009; 32: 392-398. · DOI
  35. Richardson PJ, Meany TB, Johnston GD, Kondowe G, Grimmer SF and Breckenridge AM. Comparative efficacy of lisinopril and nifedipine retard in essential hypertension: a double-blind, placebo-controlled trial. J Cardiovasc Pharmacol 1987; 10 Suppl 10: S96-98. · DOI
  36. Ryuzaki M, Nakamoto H, Nishida E, Sone M, Nakajima S, Yoshimoto M, Suzuki Y and Itagaki K. Crossover study of amlodipine versus nifedipine CR with home blood pressure monitoring via cellular phone: internet-mediated open-label crossover trial of calcium channel blockers for hypertension (i-TECHO trial). J Hypertens 2007; 25: 2352-2358. · DOI
  37. Agabiti Rosei E, Morelli P and Rizzoni D. Effects of nifedipine GITS 20 mg or enalapril 20 mg on blood pressure and inflammatory markers in patients with mild-moderate hypertension. Blood Press Suppl 2005; 1: 14-22. · DOI
  38. Weir MR, Elkins M, Liss C, Vrecenak AJ, Barr E and Edelman JM. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension. Clin Ther 1996; 18: 411-428. · DOI
  39. Chamiec T, Zaleska T, Kłoś J, Pietrzykowska H, Bednarz B and Ceremuzyński L. Efficacy and tolerance of nifedipine retard vs acebutolol in patients with essential hypertension treated for 26 weeks. Mater Med Pol 1989; 21: 49-52.
  40. Frishman WH, Garofalo JL, Rothschild A, Rothschild M, Greenberg SM and Soberman J. Multicenter comparison of the nifedipine gastrointestinal therapeutic system and long-acting propranolol in patients with mild to moderate systemic hypertension receiving diuretics. A preliminary experience. Am J Med 1987; 83: 15-19. · DOI
  41. Van Nueten L, Lacourcière Y, Vyssoulis G, Korlipara K, Marcadet DM, Dupont AG and Robertson JI. Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial. Am J Ther 1998; 5: 237-243. · DOI
  42. Douglas-Jones AP and Mitchell AD. Comparison of nifedipine (retard formulation) and mefruside in the treatment of mild to moderate hypertension--a prospective randomized double-blind crossover study in general practice. Postgrad Med J 1984; 60: 529-532. · DOI
  43. Stason WB, Schmid CH, Niedzwiecki D, Whiting GW, Caubet JF, Cory D, Luo D, Ross SD and Chalmers TC. Safety of nifedipine in angina pectoris: a meta-analysis. Hypertension 1999; 33: 24-31. · DOI
  44. Saseen JJ, Carter BL, Brown TE, Elliott WJ and Black HR. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. Hypertension 1996; 28: 109-114. · DOI
  45. Thomas G and Rahman M. Resistant hypertension in CKD. Clin J Am Soc Nephrol 2021; 16: 467-469. · DOI
  46. Dong B, Guan S, Ge B, Yan S, Qin S, Zhang B, Pin L, Li F and Wu X. Therapeutic effect and prognostic life quality of renal denervation therapy and nifedipine combined with metoprolol tartrate in the treatment of resistant hypertension. Int J Clin Exp Med 2019; 12: 13723-13731.
  47. Lv R, Chen J, Wang H, Wang J, Cheng H, Li R, Li W, Zhang T, Wei L, Chen Q, Huang J, Yu F, Shen S, Wu H, Liu C, Hong F, Liu J, Zhang X, Xiao H and Song W. Effectiveness and tolerability of nifedipine GITS in patients with chronic kidney disease and uncontrolled hypertension: a prospective, multicenter, observational study (ADRENAL). Adv Ther 2021; 38: 4771-4785. · DOI
  48. Park JB, Shin JH, Kim DS, Youn HJ, Park SW, Shim WJ, Park CG, Kim DW, Lee HY, Choi DJ, Rim SJ, Lee SY and Kim JH; FOCUS Investigators. Safety of the up-titration of nifedipine GITS and valsartan or low-dose combination in uncontrolled hypertension: the FOCUS study. Clin Ther 2016; 38: 832-842. · DOI
  49. Takeda K, Nakata T, Uchida A, Fujita H, Nakamura K, Takesako T, Itoh H, Sasaki S and Nakagawa M. Effect of combination therapy with arotinolol and sustained-release nifedipine in patients with essential hypertension resistant to monotherapy. Curr Ther Res 1994; 55: 817-827. · DOI
  50. Dargie HJ, Ford I and Fox KM. Total Ischaemic Burden European Trial (TIBET). Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. The TIBET Study Group. Eur Heart J 1996; 17: 104-112. · DOI
  51. Liu XR, Wang CA, Tang CS, Li SH, Xiao K, Peng L and Chen CX. Influence of nifedipine controlled release tablets combined with indapamide on renal function of elderly patients with refractory isolated systolic hypertension. Journal of Clinical Medicine in Practice 2014; 79-80, 93.
  52. Tanaka T, Miura S, Tanaka M, Uehara Y, Hirano T and Saku K. Efficacies of controlling morning blood pressure and protecting the kidneys by treatment with valsartan and nifedipine CR or valsartan and amlodipine (MONICA Study). J Clin Med Res 2013; 5: 432-440. · DOI
  53. Heagerty AM, Bing RF, Thurston H and Swales JD. Nifedipine substituted for minoxidil in the treatment of refractory hypertension. J Hum Hypertens 1987; 1: 83-86.
  54. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V and Desormais I; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39: 3021-3104. · DOI · Paper page
  55. Adebayo JA, Nwafor JI, Lawani LO, Esike CO, Olaleye AA and Adiele NA. Efficacy of nifedipine versus hydralazine in the management of severe hypertension in pregnancy: a randomised controlled trial. Niger Postgrad Med J 2020; 27: 317-324. · DOI
  56. Sahai R, Nidhi A, Ranjan R and Lal S. Comparative study of oral nifedipine versus intravenous labetalol in severe hypertension in pregnancy: a randomized controlled study. Int J Obstet Gynecol Res 2020; 7: 75-80. · DOI
  57. Bernstein PS, Martin JN Jr, Barton JR, Shields LE, Druzin ML, Scavone BM, Frost J, Morton CH, Ruhl C, Slager J, Tsigas EZ, Jaffer S and Menard MK. National partnership for maternal safety: consensus bundle on severe hypertension during pregnancy and the postpartum period. Anesth Analg 2017; 125: 540-547. · DOI
  58. Sridharan K and Sequeira RP. Drugs for treating severe hypertension in pregnancy: a network meta-analysis and trial sequential analysis of randomized clinical trials. Br J Clin Pharmacol 2018; 84: 1906-1916. · DOI
  59. Scardo JA, Vermillion ST, Newman RB, Chauhan SP and Hogg BB. A randomized, double-blind, hemodynamic evaluation of nifedipine and labetalol in preeclamptic hypertensive emergencies. Am J Obstet Gynecol 1999; 181: 862-866. · DOI
  60. Alam A and Zakaria S. Oral nifedipine versus intravenous labetalol for acute blood pressure control in hypertensive emergencies of pregnancy: a randomized controlled trial. Int J Reprod Contracept Obstet Gynecol 2019; 8: 1921-1928. · DOI
  61. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr and Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572. · DOI · Paper page
  62. Brown MA, Buddle ML, Farrell T and Davis GK. Efficacy and safety of nifedipine tablets for the acute treatment of severe hypertension in pregnancy. Am J Obstet Gynecol 2002; 187: 1046-1050. · DOI
  63. Bortolus R, Ricci E, Chatenoud L and Parazzini F. Nifedipine administered in pregnancy: effect on the development of children at 18 months. BJOG 2000; 107: 792-794. · DOI
  64. Songthamwat S, Na Nan C and Songthamwat M. Effectiveness of nifedipine in threatened preterm labor: a randomized trial. Int J Womens Health 2018; 10: 317-323. · DOI
  65. Houtzager BA, Hogendoorn SM, Papatsonis DN, Samsom JF, van Geijn HP, Bleker OP and van Wassenaer AG. Long-term follow up of children exposed in utero to nifedipine or ritodrine for the management of preterm labour. BJOG 2006; 113: 324-331. · DOI
  66. Easterling T, Mundle S, Bracken H, Parvekar S, Mool S, Magee LA, von Dadelszen P, Shochet T and Winikoff B. Oral antihypertensive regimens (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomised controlled trial. Lancet 2019; 394: 1011-1021. · DOI
  67. Cleary EM, Racchi NW, Patton KG, Kudrimoti M, Costantine MM and Rood KM. Trial of intrapartum extended-release nifedipine to prevent severe hypertension among pregnant individuals with preeclampsia with severe features. Hypertension 2023; 80: 335-342. · DOI
  68. Khan D, Badhan R, Kirby DJ, Bryson S, Shah M and Mohammed AR. Virtual clinical trials guided design of an age-appropriate formulation and dosing strategy of nifedipine for paediatric use. Pharmaceutics 2023; 15: 556. · DOI
  69. Zapata F, Fernandez C, de Rovetto C, de Castaño I, Roa JA and Echandía CA. Nifedipine and captopril in hypertensive crisis in children. Colombia Médica 2006; 37: 189-195. · DOI
  70. Yiu V, Orrbine E, Rosychuk RJ, MacLaine P, Goodyer P, Girardin C, Gowrishankar M, Ogborn M, Midgley J, Filler G and Harley F. The safety and use of short-acting nifedipine in hospitalized hypertensive children. Pediatr Nephrol 2004; 19: 644-650. · DOI
  71. Nourse PJ and McCulloch MI. Evaluation of the safety of shortacting nifedipine use in children with severe hypertension secondary to acute post-streptococcal glomerulonephritis. S Afr J Child Health 2007; 1: 34-37.
  72. Blaszak RT, Savage JA and Ellis EN. The use of short-acting nifedipine in pediatric patients with hypertension. J Pediatr 2001; 139: 34-37. · DOI
  73. Tuleu C, Grangé J and Seurin S. The need for pædiatric formulation: oral administration of nifedipine in children, a proof of concept. J Drug Deliv Sci Technol 2005; 15: 319-324. · DOI
  74. Jung SY, Choi NK, Kim JY, Chang Y, Song HJ, Lee J and Park BJ. Short-acting nifedipine and risk of stroke in elderly hypertensive patients. Neurology 2011; 77: 1229-1234. · DOI
  75. Schubert I, Hein R, Abbas S and Thürmann P. The frequency of prescription of immediate-release nifedipine for elderly patients in Germany: utilization analysis of a substance on the PRISCUS list of potentially inappropriate medications. Dtsch Arztebl Int 2012; 109: 215-219. · DOI
  76. Bonaduce D, Canonico V, Petretta M, Forgione L, Ianniciello A, Cavallaro V, Bertocchi F and Rengo F. Twenty-four-hour blood pressure monitoring during treatment with extended-release felodipine versus slow-release nifedipine in elderly patients with mild to moderate hypertension: a randomized, double-blind, cross-over study. Eur J Clin Pharmacol 1997; 53: 95-100. · DOI
  77. Duckett GK and Cheadle B. Hypertension in the elderly: a study of a combination of atenolol and nifedipine. Br J Clin Pract 1990; 44: 52-54. · DOI
  78. Bravo EL, Krakoff LR, Tuck ML and Friedman CP. Antihypertensive effectiveness of nifedipine gastrointestinal therapeutic system in the elderly. The Modern Approach to the Treatment of Hypertension (MATH) Study Group. Am J Hypertens 1990; 3: 326S-332S. · DOI · Paper page
  79. Gong L, Zhang W, Zhu Y, Zhu J, Kong D, Pagé V, Ghadirian P, LeLorier J and Hamet P. Shanghai trial of nifedipine in the elderly (STONE). J Hypertens 1996; 14: 1237-1245. · DOI
  80. Wang X, Wu J, Liu L, Yang Q, Yu H, Luo W and Yan Z. Clinical effect of combined controlled-release nifedipine tablets-valsartan therapy on elderly patients suffering from type II diabetic nephropathy with hypertension. Biomed Res (India) 2018; 29: 1133-1136. · DOI
  81. Wang XJ, Wu JR, Liu L, Yang Q, Yu HL, Luo WH and Yan ZX. Clinical effect of combined controlled-release nifedipine tablets-valsartan therapy on elderly patients suffering from type II diabetic nephropathy with hypertension. Biomed Res 2018; 29. · DOI
  82. Schneider R, Stolero D, Griffel L, Kobelt R, Brendel E and Iaina A. Pharmacokinetic profile of nifedipine GITS in hypertensive patients with chronic renal impairment. Drugs 1994; 48 Suppl 1: 16-21; discussion 21-22. · DOI
  83. Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, Origasa H, Iimura O, Ishii M, Saruta T, Arakawa K, Hosoda S and Kawai C; Japan Multicenter Investigation for Cardiovascular Diseases-B Study Group. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 2004; 27: 181-191. · DOI
  84. Yui Y, Sumiyoshi T, Kodama K, Hirayama A, Nonogi H, Kanmatsuse K, Origasa H, Iimura O, Ishii M, Saruta T, Arakawa K, Hosoda S and Kawai C. Nifedipine retard was as effective as angiotensin converting enzyme inhibitors in preventing cardiac events in high-risk hypertensive patients with diabetes and coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) subgroup analysis. Hypertens Res 2004; 27: 449-456. · DOI
  85. Baba S; J-MIND Study Group. Nifedipine and enalapril equally reduce the progression of nephropathy in hypertensive type 2 diabetics. Diabetes Res Clin Pract 2001; 54: 191-201. · DOI
  86. Mancia G, Brown M, Castaigne A, de Leeuw P, Palmer CR, Rosenthal T, Wagener G and Ruilope LM; INSIGHT. Outcomes with nifedipine GITS or Co-amilozide in hypertensive diabetics and nondiabetics in Intervention as a Goal in Hypertension (INSIGHT). Hypertension 2003; 41: 431-436. · DOI
  87. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T and Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366-372. · DOI
  88. Webster K, Fishburn S, Maresh M, Findlay SC and Chappell LC; Guideline Committee. Diagnosis and management of hypertension in pregnancy: summary of updated NICE guidance. BMJ 2019; 366: l5119. · DOI
  89. Constantine G, Beevers DG, Reynolds AL and Luesley DM. Nifedipine as a second line antihypertensive drug in pregnancy. Br J Obstet Gynaecol 1987; 94: 1136-1142. · DOI
  90. Shen X, Yan J and Ren A. Effect of long-acting nifedipine on blood pressure level, eutocia rate and neonatal health status in patients with pregnancy-induced hypertension. Int J Clin Exp Med 2019; 12: 2605-2611.

Metadata

Authors
Hazra, P. K.
Corresponding author
Hazra, Prakash Kumar
Venue
American Journal of Cardiovascular Disease
Publisher
e-Century Publishing Corporation
Published
2024
Volume
14
Issue
6
Pages
396-413
ISSN
2160-200X (ISSN-L)
DOI
10.62347/rpmz6407
PMC
PMC11744219
OpenAlex
W4406134311
Cited by
11
References
4
Citations by year
2026: 5 · 2025: 6
FWCI
0.81
Type
journal article
Language
en
Open access
Locations
  • American Journal of Cardiovascular Disease (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
Keywords
essential hypertension, calcium channel blockers, blood pressure control, resistant hypertension, hypertension in pregnancy, gastrointestinal therapeutic system, tachycardia, chronic kidney disease, diabetes mellitus, antihypertensive efficacy and safety

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review